[go: up one dir, main page]

PE20090931A1 - Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Info

Publication number
PE20090931A1
PE20090931A1 PE2008001841A PE2008001841A PE20090931A1 PE 20090931 A1 PE20090931 A1 PE 20090931A1 PE 2008001841 A PE2008001841 A PE 2008001841A PE 2008001841 A PE2008001841 A PE 2008001841A PE 20090931 A1 PE20090931 A1 PE 20090931A1
Authority
PE
Peru
Prior art keywords
liasa
pharmaceutical composition
composition containing
steroid inhibitor
thiofen
Prior art date
Application number
PE2008001841A
Other languages
English (en)
Inventor
Masuo Yamaoka
Takahito Hara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20090931A1 publication Critical patent/PE20090931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN INHIBIDOR DE ESTEROIDE C17,20 LIASA DE FORMULA (I) DONDE n ES DE 1 A 3; Ar ES UN COMPUESTO DE FORMULA (1), (2), ENTRE OTROS, DONDE m1 ES DE 1 A 4; m2 ES DE 0 A 3; R1 Y R2 SON CADA UNO H, HIDROXILO, TIOL, AMINO, ENTRE OTROS; m3 ES DE 1 A 5; m4 ES DE 0 A 4; R3 Y R4 SON CADA UNO H, HIDROXILO, ACILO, AMINO, ENTRE OTROS; SIENDO COMPUESTOS PREFERIDOS: (+/-)-7-(5-METOXIBENZO[b]TIOFEN-2-IL)-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-OL, (+/-)-7-(5-FLUOROBENZO[b]TIOFEN-2-IL)-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-OL, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA INDEPENDIENTE DE ANDROGENOS
PE2008001841A 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa PE20090931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007280813 2007-10-29

Publications (1)

Publication Number Publication Date
PE20090931A1 true PE20090931A1 (es) 2009-08-03

Family

ID=40591618

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Country Status (17)

Country Link
US (2) US20100261689A1 (es)
EP (1) EP2205239A2 (es)
JP (1) JP5430576B2 (es)
KR (1) KR20100088144A (es)
CN (1) CN101909622B (es)
AR (1) AR069079A1 (es)
AU (1) AU2008319767B8 (es)
CA (1) CA2703780A1 (es)
CL (1) CL2008003198A1 (es)
IL (1) IL205368A (es)
MX (1) MX2010004405A (es)
NZ (1) NZ585473A (es)
PE (2) PE20130603A1 (es)
RU (1) RU2481107C2 (es)
SG (1) SG185930A1 (es)
TW (1) TWI426901B (es)
WO (1) WO2009057795A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
WO2012158884A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710208B2 (en) * 1996-02-14 1999-09-16 Hoechst Marion Roussel, Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
AR034854A1 (es) * 2000-11-17 2004-03-24 Takeda Chemical Industries Ltd Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto
CA2700690C (en) * 2002-01-10 2013-09-10 Takeda Pharmaceutical Company Limited Process for producing reformatsky reagent in stable form
CA2522784C (en) * 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS

Also Published As

Publication number Publication date
US20100261689A1 (en) 2010-10-14
WO2009057795A2 (en) 2009-05-07
WO2009057795A3 (en) 2009-07-09
SG185930A1 (en) 2012-12-28
AR069079A1 (es) 2009-12-30
RU2481107C2 (ru) 2013-05-10
RU2010121765A (ru) 2011-12-10
CN101909622B (zh) 2013-06-19
AU2008319767A8 (en) 2014-01-09
AU2008319767B8 (en) 2014-01-09
TW200927097A (en) 2009-07-01
JP2011502114A (ja) 2011-01-20
AU2008319767A1 (en) 2009-05-07
CL2008003198A1 (es) 2009-12-18
JP5430576B2 (ja) 2014-03-05
MX2010004405A (es) 2010-05-03
NZ585473A (en) 2012-03-30
WO2009057795A8 (en) 2010-05-14
IL205368A0 (en) 2010-12-30
EP2205239A2 (en) 2010-07-14
PE20130603A1 (es) 2013-05-30
AU2008319767B2 (en) 2013-12-19
TWI426901B (zh) 2014-02-21
CA2703780A1 (en) 2009-05-07
IL205368A (en) 2014-08-31
KR20100088144A (ko) 2010-08-06
US20140256693A1 (en) 2014-09-11
AU2008319767A2 (en) 2010-06-17
CN101909622A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
UY29530A1 (es) Compuestos quimicos
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
PE20090156A1 (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
GT200500237A (es) Derivados de pirimidina
NZ596834A (en) Prlr-specific antibody and uses thereof
NZ580226A (en) Dimer compounds as inhibitors of iap
UY30748A1 (es) Compuesto0s novedosos
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
MX2007014132A (es) Compuestos de diarilhidantoina.
DK1853602T3 (da) Kemiske forbindelser
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
EA201100037A1 (ru) Органические соединения
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
PT1853588E (pt) Compostos químicos
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
DE60328010D1 (de) Heterocyclische verbindungen
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью

Legal Events

Date Code Title Description
FC Refusal